MX2023002953A - Inhibidores de proteína tirosina fosfatasa y métodos para su uso. - Google Patents

Inhibidores de proteína tirosina fosfatasa y métodos para su uso.

Info

Publication number
MX2023002953A
MX2023002953A MX2023002953A MX2023002953A MX2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A MX 2023002953 A MX2023002953 A MX 2023002953A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
MX2023002953A
Other languages
English (en)
Inventor
Andrew Bogdan
Jennifer M Frost
Philip R Kym
Eric Voight
Zhaoming Xiong
Christos Economou
Elliot P Farney
Stacy Fosu
Spencer O Scholz
Original Assignee
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc filed Critical Calico Life Sciences Llc
Publication of MX2023002953A publication Critical patent/MX2023002953A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se proporcionan compuestos, que incluyen compuestos con la fórmula (I), composiciones y métodos útiles para la inhibición de la proteína tirosina fosfatasa, por ejemplo, la proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y/o la proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento de enfermedades, afecciones y trastornos relacionados que responden favorablemente al tratamiento con inhibidores de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
MX2023002953A 2020-09-11 2021-09-10 Inhibidores de proteína tirosina fosfatasa y métodos para su uso. MX2023002953A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063077330P 2020-09-11 2020-09-11
PCT/US2021/049895 WO2022056281A1 (en) 2020-09-11 2021-09-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023002953A true MX2023002953A (es) 2023-06-01

Family

ID=78212618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002953A MX2023002953A (es) 2020-09-11 2021-09-10 Inhibidores de proteína tirosina fosfatasa y métodos para su uso.

Country Status (7)

Country Link
EP (1) EP4211122A1 (es)
JP (1) JP2023542503A (es)
CN (1) CN116829555A (es)
AU (1) AU2021342161A1 (es)
CA (1) CA3191842A1 (es)
MX (1) MX2023002953A (es)
WO (1) WO2022056281A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202337459A (zh) * 2022-02-02 2023-10-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
US20240207238A1 (en) * 2022-11-09 2024-06-27 Bristol-Myers Squibb Company Inhibitors of protein tyrosine phosphatase, compositions, and methods of use
WO2024138216A2 (en) * 2022-12-23 2024-06-27 Case Western Reserve University Compositions and methods for treating and detecting cancer
CN115819330A (zh) * 2022-12-28 2023-03-21 天津均凯农业科技有限公司 一种连续化制备2-氨基甲基-3-氯-5-三氟甲基吡啶的方法
WO2024141015A1 (en) * 2022-12-30 2024-07-04 Insilico Medicine Ip Limited Protein tyrosine phosphatase inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
EP3938038A1 (en) * 2019-03-14 2022-01-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
AU2021342161A9 (en) 2024-02-08
EP4211122A1 (en) 2023-07-19
JP2023542503A (ja) 2023-10-10
WO2022056281A1 (en) 2022-03-17
CN116829555A (zh) 2023-09-29
AU2021342161A1 (en) 2023-05-25
CA3191842A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
MX2021010544A (es) Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2024000820A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
SA521422303B1 (ar) مثبطات عضو عائلة الكنيسين 18 أ
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
ATE424208T1 (de) Proteinkinaseinhibitoren
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
MX2022014637A (es) Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
EA200300442A1 (ru) Способы и композиции для лечения воспалительных заболеваний
MX2024002131A (es) Inhibidores de la 17-beta-hidroxisteroide deshidrogenasa tipo 13 y metodos de uso de los mismos.
MX2021010829A (es) Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb).
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).
WO2024137548A3 (en) Inhibitors of jak2
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
MX2023010692A (es) Compuestos que tienen tetrahidroindolizina-1-carboxamida como inhibidores de bcl-2.
MA53135B1 (fr) Composés de c-mannoside utiles pour le traitement d'infections des voies urinaires